SCHEMBL2481763

SCHEMBL2481763

CCOC(=O)c1csc2c(-c3ccncc3)c(-c3cccc([N+](=O)[O-])c3)nn12

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 3/20 0.49
PDE4D Q08499 3/20 0.49
PDE4A P27815 1/20 0.49
PDE4C Q08493 1/20 0.49
MAPT P10636 8/20 0.48
ALDH1A1 P00352 5/20 0.48
MAPK1 P28482 1/20 0.48
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
RAB9A P51151 1/20 0.45
SLC6A2 P23975 1/20 0.44
SLC6A4 P31645 1/20 0.44
SLC6A3 Q01959 1/20 0.44
ALOX12 P18054 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.42
LMNA P02545 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
AMY1A P0DUB6 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2477754 0.85 SMN1; SMN2 (0.46) MAPTALDH1A1MAPK1MEN1KMT2A
SCHEMBL2480456 0.77 BRAF (0.53) MAPT
SCHEMBL2507570 0.75 PDE4B (0.44) PDE4BPDE4DPDE4APDE4CMAPT
SCHEMBL2477600 0.72 MAPT (0.44) PDE4BPDE4DPDE4APDE4CMAPT
SCHEMBL27086172 0.70 MAPT (0.55) PDE4BPDE4DPDE4APDE4CMAPT
SCHEMBL27085913 0.69 PDE4B (0.57) PDE4BPDE4DPDE4APDE4CMAPT
SCHEMBL6437170 0.69 MAPT (0.56) PDE4BPDE4DPDE4APDE4CMAPT
SCHEMBL11400231 0.69 MAPT (0.55) PDE4BPDE4DPDE4APDE4CMAPT
SCHEMBL7091428 0.69 MAPT (0.61) MAPTALDH1A1MAPK1MEN1KMT2A
SCHEMBL7089405 0.69 RAB9A (0.75) PDE4BPDE4DPDE4APDE4CMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8524707-B2 Bicyclic pyrazoles as protein kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2013-09-03 US disclosed
EP-2373664-B1 BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2013-06-12 EP disclosed
US-20110257165-A1 BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-10-20 US disclosed
EP-2373664-A1 BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS Nerviano Medical Sciences S.r.l. (IT) 2011-10-12 EP disclosed
WO-2010070060-A1 BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2010-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110257165-A1 BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS MAP3K19, MAP4K3, MAP3K15 PDE4B 712/4885PDE4D 996/4885PDE4A 786/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.